Close Menu
    Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Biodetection

    OraSure Awarded $13.6M From BARDA to Advance COVID-19 Rapid Test

    By Global Biodefense StaffSeptember 23, 2021
    Credit: OraSure via MedicalCountermeasures.gov
    Share
    Facebook LinkedIn Reddit Email

    BARDA renews collaboration with OraSure Technologies to support InteliSwab™ COVID-19 Rapid Test 510(k) Clearance and CLIA Waiver

    BARDA and OraSure Technologies, Inc. are partnering again, this time to advance their rapid antigen test for SARS-CoV-2 to U.S. Food and Drug Administration (FDA) 510(k) clearance.

    InteliSwab™ is a simple “swab, swirl, and see” test that uses an integrated swab to self-collect a sample from the lower nostrils. The result appears right on the test stick within 30 minutes, with no instruments, batteries, smartphone or laboratory analysis needed. It has three Emergency Use Authorizations from the Food and Drug Administration for professional point-of-care use, prescription (Rx) home use, and over-the-counter (OTC) use.

    BARDA supported development of the OraSure InteliSwab test from inception through Emergency Use Authorization (EUA) for over-the-counter (InteliSwab COVID-19 Rapid Test), prescription home use (InteliSwab COVID-19 Rapid Test Rx), and professional point-of-care use (InteliSwab COVID-19 Rapid Test Pro). These tests received EUA in June 2021.

    The 510(k) clearance and CLIA waiver for this test will ensure InteliSwab continues to be available on the market even after the public health emergency is declared over.

    The InteliSwab test targets the detection of all clinically relevant SARS-CoV-2 variants of concern, as qualified by the U.S. Centers for Disease Control and Prevention (CDC). Currently there are no rapid point-of-care antigen tests available with 510(k) clearance.

    DoD Procures InteliSwab COVID-19 Rapid Tests for Nearly 25,000 Sites

    The Defense Logistics Agency earlier this month awarded OraSure a procurement contract for its InteliSwab™ COVID-19 Rapid Test for over-the-counter use, which the Defense Logistics Agency estimated to have a value of $205 million.

    Under the terms of the contract, OraSure will provide its InteliSwab™ COVID-19 Rapid Test to up to 25,000 sites throughout the United States as part of the National pandemic response and the tests will be funded by the U.S. federal government. The contract will run from October 2021 through September 2022.

    Sources: BARDA, OraSure Technologies, Inc., Defense.gov

    ASPR Awards BARDA COVID-19 Editor Pick Emergency Use Authorization HHS POC Diagnostics Public Health Emergency SARS
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleNobody is Checking for Violations of the Biological Weapons Convention
    Next Article Puerto Rico National Guard Validates COVID-19 Vaccination Data for over 600,000 Citizens

    Related Stories

    First Light Diagnostics Receives FDA Clearance for Rapid Anthrax Test

    December 5, 2023

    Chlorine Exposure Biomarkers in a Large Animal Model

    December 5, 2023

    ARPA-H Announces New Tiered Proposal Submission System to Reduce Applicant Barriers

    December 5, 2023

    Needle-Free Vaccine Patch Against Zika Virus

    December 2, 2023
    News Scan

    Biodefense Headlines – 30 November 2023

    News Scan November 30, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include the largest ever outbreak of mpox in the DRC; launch of National Wastewater Surveillance Program dashboard; low uptake of COVID-19 boosters and flu vaccines;…

    Upcoming Events

    Mar 12
    Hybrid Hybrid Event
    March 12, 2024 - March 17, 2024

    2024 Fungal Genetics Conference

    Mar 21
    March 21, 2024 - March 23, 2024

    ASPPH 2024 Annual Meeting

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    News on pathogens and preparedness for public health emergencies

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.